BIO-TECHNE Corp Accounts Payable
BIO-TECHNE Corp (TECH) had Accounts Payable of $26.70 million as of 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-24
- 2026-06-30: Accounts Payable, Current $26.70M.
- 2026-03-31: Accounts Payable, Current $23.49M.
- 2025-12-31: Accounts Payable, Current $26.27M.
- 2025-09-30: Accounts Payable, Current $30.16M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $26.70M 10-K · filed 2026-08-24 |
| 2026-03-31 | $23.49M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $26.27M 10-Q · filed 2026-02-04 |
| 2025-09-30 | $30.16M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $25.31M 10-K · filed 2026-08-24 |
| 2025-03-31 | $31.64M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $33.12M 10-Q · filed 2025-02-06 |
| 2024-09-30 | $31.56M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $37.97M 10-K · filed 2025-08-22 |
| 2024-03-31 | $28.89M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $31.51M 10-Q · filed 2024-02-07 |
| 2023-09-30 | $28.08M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $25.68M 10-K · filed 2024-08-22 |
| 2023-03-31 | $27.12M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $24.10M 10-Q · filed 2023-02-07 |
| 2022-09-30 | $30.48M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $33.87M 10-K · filed 2023-08-23 |
| 2022-03-31 | $30.86M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $26.76M 10-Q · filed 2022-02-07 |
| 2021-09-30 | $25.62M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $29.38M 10-K · filed 2022-08-24 |
| 2021-03-31 | $25.84M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $24.25M 10-Q · filed 2021-02-08 |
| 2020-09-30 | $27.19M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $23.09M 10-K · filed 2021-08-25 |
| 2020-03-31 | $19.73M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $19.09M 10-Q · filed 2020-02-06 |
| 2019-09-30 | $14.11M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $16.21M 10-K · filed 2020-08-26 |
| 2019-03-31 | $14.90M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $16.01M 10-Q · filed 2019-02-07 |
| 2018-09-30 | $18.26M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $18.45M 10-K/A · filed 2019-11-06 |
| 2018-03-31 | $14.53M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $11.32M 10-Q · filed 2018-02-08 |
| 2017-09-30 | $15.08M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $16.86M 10-K · filed 2018-08-27 |
| 2017-03-31 | $12.03M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $12.91M 10-Q · filed 2017-02-09 |
| 2016-09-30 | $14.18M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $20.65M 10-K · filed 2017-09-07 |
| 2016-03-31 | $13.52M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $10.43M 10-Q · filed 2016-02-09 |
| 2015-09-30 | $13.18M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $13.44M 10-K · filed 2016-08-29 |
| 2015-03-31 | $13.51M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $13.13M 10-Q · filed 2015-02-09 |
| 2014-09-30 | $13.57M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $9.65M 10-K · filed 2015-08-31 |
| 2014-03-31 | $8.42M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $7.16M 10-Q · filed 2014-02-04 |
| 2013-09-30 | $6.66M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $6.24M 10-K · filed 2014-08-29 |
| 2013-03-31 | $6.19M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $6.47M 10-Q · filed 2013-02-11 |
| 2012-09-30 | $6.54M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $6.29M 10-K · filed 2013-08-29 |
| 2012-03-31 | $6.45M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $5.91M 10-Q · filed 2012-02-07 |
| 2011-09-30 | $5.73M 10-Q · filed 2011-11-09 |
| 2011-06-30 | $5.21M 10-K · filed 2012-08-29 |
| 2011-03-31 | $5.03M 10-Q · filed 2011-05-10 |
| 2010-12-31 | $3.92M 10-Q · filed 2011-02-09 |
| 2010-09-30 | $4.35M 10-Q · filed 2010-11-09 |
| 2010-06-30 | $5.23M 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |